Contineum Therapeutics(CTNM)

Focus: Contineum Therapeutics is a public-stage biotech focused on small-molecule therapeutics for multiple sclerosis and respiratory diseases. The company operates with a lean R&D footprint and minimal revenue base, positioning it as an early-stage, discovery-focused player.

Neurology Respiratory

Profile data last refreshed 6h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

1-1 this month

Stable — net -1 jobs in 30d

0 added, 1 removed. Backfill posture.

Should You Work at Contineum Therapeutics?

AI assessment

Continuum is a high-risk, science-driven opportunity suited only for researchers seeking early-stage upside and tolerant of potential restructuring; unsuitable for those seeking stability or near-term career progression.

Why Work Here

Multi-indication pipeline with 8 programs across neurology and respiratory, including Phase 2 advancement in IPF and RRMS offering progression visibility.

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Early-stage

8 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$50M

Pipeline & Clinical Trials

PIPE-307

Multiple Sclerosis

PHASE_1

Clinical Trials (1)

NCT04725175Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy Volunteers

Phase 1

Help build intelligence for Contineum Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company status provides liquidity and institutional credibility, with recent investor conferences (Goldman Sachs 2026) signaling market engagement.

Focused therapeutic areas (MS, respiratory, pain, hearing loss) allow deep specialization in high-unmet-need indications.

Watch Out For

Severe cash burn: FY 2025 net loss of $42.3M against only $22M cash on hand signals potential funding pressure or equity raise dilution within 12 months.
Insider selling by CSO (June 2026) and minimal hiring (2 active roles across all departments) suggest low near-term growth momentum and possible leadership confidence concerns.
No marketed products, no Phase 3 programs, and no PDUFA catalysts in pipeline mean 3–5 years minimum to any clinical validation milestone.

Generated by Claude from Contineum Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

PIPE-791

Chronic Osteoarthritis Pain

PHASE_1

Clinical Trials (1)

NCT06810245Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain

Phase 1

PIPE-791

Multiple Sclerosis

PHASE_1

Clinical Trials (1)

NCT05983939Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers

Phase 1

PIPE-791

Idiopathic Pulmonary Fibrosis (IPF)

PHASE_1

Clinical Trials (1)

NCT06683612PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF

Phase 1

PIPE-307

Multiple Sclerosis

PHASE_1

Clinical Trials (1)

NCT04941781PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers

Phase 1

PIPE-505

Sensorineural Hearing Loss

PHASE_1_2

Clinical Trials (1)

NCT04462198Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss

Phase 1/2

PIPE-791 Dose A

Idiopathic Pulmonary Fibrosis

PHASE_2

Clinical Trials (1)

NCT07284459Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

Phase 2

Interview Prep Quick Facts

Portfolio: 7 clinical trials

Top TAs: Neurology, Respiratory

Publications: 9 in PubMed

SEC Filings: 2 available

Open Roles: 1 active job

Therapeutic Area Focus

Neurology

4 pipeline

Respiratory

2 pipeline

Marketed

Pipeline

Financials (FY2025)

R&D Spend

$38M39%

Net Income

-$42M

Cash

$22M

Source: SEC 10-K Filing

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(9)

Recent peer-reviewed publications with author affiliations at this company

Discovery of PIPE-791, A Potent and Brain-Penetrant Lysophosphatidic Acid Receptor 1 Antagonist with Slow Tight Binding Characteristics for the Treatment of Neuroinflammatory Disorders.

Journal of medicinal chemistry

2026

PMID:42370792

Additives Promote Divergent Reactivity in Photolytic Deoxygenation and Lactonization Reactions of Cobalt Alkoxycarbonyls.

European journal of organic chemistry

2026

PMID:42100026